Investigating the effect of Remifentanil and Labtalol on hemodynamic changes

Phase 3

Recruiting

• Conditions: Condition 1: Hemodynamic changes. Condition 2: Bleeding rate. Condition 3: arrhythmia.; Cardiac arrhythmia, unspecified; I49.9

• Registration Number: IRCT20221119056535N1
• Lead Sponsor: Qazvin University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Willingness to participate in research with informed consent after giving necessary and sufficient explanations about the study
The age of the person should be between 15 and 60 years
There is no history of surgery and it is the patient's first surgery
Not having a chronic mental or physical illness (schizophrenia, diabetes, etc.)
Not having vision and hearing problems and other disabilities
No allergy to Remifentanil, Profol and Labtalol
Absence of pregnancy, breastfeeding and abortion less than 3 months

Exclusion Criteria

Heart diseases and HTN
Liver diseases (cirrhosis, hepatitis, etc.)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding. Timepoint: First, three minutes after the start of induction, then three and five minutes and then ten minutes. Method of measurement: ECG, pulse oximeter, non-invasive blood pressure measurement.